Wu, X.-M.; Qian, Y.-K.; Chen, H.-L.; Hu, C.-H.; Chen, B.-W.
Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis. Curr. Oncol. 2023, 30, 8444-8463.
https://doi.org/10.3390/curroncol30090615
AMA Style
Wu X-M, Qian Y-K, Chen H-L, Hu C-H, Chen B-W.
Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis. Current Oncology. 2023; 30(9):8444-8463.
https://doi.org/10.3390/curroncol30090615
Chicago/Turabian Style
Wu, Xian-Meng, Yong-Kang Qian, Hua-Ling Chen, Chen-Hua Hu, and Bing-Wei Chen.
2023. "Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis" Current Oncology 30, no. 9: 8444-8463.
https://doi.org/10.3390/curroncol30090615
APA Style
Wu, X. -M., Qian, Y. -K., Chen, H. -L., Hu, C. -H., & Chen, B. -W.
(2023). Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis. Current Oncology, 30(9), 8444-8463.
https://doi.org/10.3390/curroncol30090615